Search

Ramiro M Malgor

from Athens, OH
Age ~59
Get Report
Also known as:
Ramiro E
Phone and address:
24 Home St, Shade, OH 45701
(740) 592-6997
Connected to:
Michael W Malguarnera, 36David L Malhalab, 74Ryan Z Malham, 35Arvind Malhan, 52Bhuvan Malhan, 40Madhu Malhan, 59Mohit Malhan, 39Sami L Malhas, 44Cristina R Malheiro, 50Rafael O Malheiros, 39

Ramiro Malgor Phones & Addresses

  • 24 Home St, Athens, OH 45701 (740) 592-6997

Resumes

Resumes

Ramiro Malgor Photo 1

Associate Professor

View page
Location:
Athens, OH
Industry:
Research
Work:
Ohio University
Associate Professor
Ramiro Malgor Photo 2

Ramiro Malgor

View page
Location:
1 Pleasantview Dr, Athens, OH 45701
Industry:
Research
Work:
Ohio University
M.d
Skills:
Cell Culture
Clinical Research
Research
Medical Education
Public Speaking
Teaching
Higher Education
Molecular Biology
Western Blotting
Elisa
Life Sciences
Public Health

Publications

Us Patents

Methods And Compositions For The Treatment Of Malignant Melanoma, Breast, Prostate, Colon, Papillary Thyroid And Pancreatic Cancer

View page
US Patent:
20100004304, Jan 7, 2010
Filed:
Oct 1, 2008
Appl. No.:
12/286880
Inventors:
Leonard D. Kohn - Woodinville WA, US
Douglas J. Goetz - Athens OH, US
Kelly D. McCall - Shade OH, US
Anthony Schwartz - Vienna WV, US
Frank Schwartz - Vienna WV, US
Ramiro Malgor - Athens OH, US
Glorglo Napolitano - Montesilvano (PE), IT
Cesidio Giullant - Roccamonce, IT
International Classification:
A61K 31/4164
C12N 5/06
US Classification:
514396, 435375
Abstract:
It is now recognized that chronic inflammation is an important risk factor for the development of cancer. The proinflammatory cytokine IL-6 is implicated in cancer because it is important for the activation of STAT, a key regulator of cancer growth, survival, metastasis, immune evasion and angiogenesis. Increased IL-6 and Stat-3 exists in vitro in pancreatic cancer, malignant melanoma, papillary thyroid cancer, breast cancer, colon cancer, and prostate cancer cells with high basal expression of Toll-like receptor 3 (TLR3) and Wnt5a. IL6/STAT3 activation, mediated by overexpressed TLR3 signaling, appears important in the tumor growth process, it may increase Wnt5a signaling, and be associated with increased cellular growth and migration. Using a novel inhibitor of pathologic TLR3 signaling (5-phenylmethimazole [C10]) we have demonstrated decreases in these markers plus suppression of cell growth and migration in human pancreatic cancer, malignant melanoma, papillary thyroid cancer, breast cancer, colon cancer, and prostate cancer cells.

Use Of Phenylmethimazoles, Methimazole Derivatives, And Tautomeric Cyclic Thiones For The Treatment Of Autoimmune/Inflammatory Diseases Associated With Toll-Like Receptor Overexpression

View page
US Patent:
20060211752, Sep 21, 2006
Filed:
May 17, 2005
Appl. No.:
11/130922
Inventors:
Leonard Kohn - Athens OH, US
Norikazu Harii - Yaminashi, JP
Uruguaysito Benavides-Peralta - Montevideo, UY
Mariana Gonzalez-Murguiondo - Montevideo, UY
Christopher Lewis - Athens OH, US
Giorgio Napolitano - Pescara, IT
Cesidio Giuliani - Roccamonce, IT
Ramiro Malgor - Athens OH, US
Douglas Goetz - Athens OH, US
International Classification:
A61K 31/4166
US Classification:
514389000
Abstract:
The present invention relates to the treatment of autoimmune and/or inflammatory diseases associated with overexpression of Toll-like receptor 3 (TLR3) as well as Toll-like receptor 4 (TLR4) and/or TLR3/TLR4 signaling in nonimmune cells, monocytes, macrophages, and/or dendritic cells in association with related pathologies. This invention also relates to the use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune and inflammatory diseases associated with Toll-like receptor 3 (TLR3) as well as Toll-like receptor 4 (TLR4) and/or TLR3/TLR4 signaling in nonimmune cells, monocytes, macrophages, and/or dendritic cells in association with related pathologies. This invention also relates to treating a subject having a disease or condition associated with abnormal Toll-like receptor 3 as well as Toll-like receptor 4 and/or TLR3/TLR4 signaling in nonimmune cells, monocytes, macrophages, and/or dendritic cells in association with related pathologies. The present invention also relates to the treatment of autoimmune-inflammatory pathologies and chemokine and cytokine-mediated diseases associated with TLR overexpression and signaling. This invention also relates to pharmaceutical formulations capable of inhibiting the IRF-3/Type 1 IFN/STAT/ISRE/IRF-1 pathway associated with Toll-like receptor overexpression or signaling.

Prevention And Treatment Of Non-Alcoholic Fatty Liver Disease

View page
US Patent:
20160256439, Sep 8, 2016
Filed:
Oct 31, 2014
Appl. No.:
15/032508
Inventors:
- Athens OH, US
Frank L. Schwartz - Vienna WV, US
Douglas J. Goetz - Athens OH, US
Ramiro Malgor - Athens OH, US
Assignee:
Ohio University - Athens OH
International Classification:
A61K 31/4184
A61K 45/06
A61K 31/4164
Abstract:
Methods for preventing, treating, and/or reducing the risk of developing non-alcoholic fatty liver disease in a subject in need thereof and pharmaceutical compositions for the prevention or treatment of non-alcoholic fatty liver disease. The methods include administering a therapeutically effective amount of phenylmethimazole, methimazole derivatives, and/or tautomeric cyclic thiones to the subject. The pharmaceutical composition includes phenylmethimazole, methimazole derivatives, and/or tautomeric cyclic thiones formulated for administration to a subject for the prevention or treatment of non-alcoholic fatty liver disease.

Use Of Phenylmethimazoles, Methimazole Derivatives, And Tautomeric Cyclic Thiones For The Treatment Of Autoimmune/Inflammatory Diseases Associated With Toll-Like Receptor Overexpression

View page
US Patent:
20160220536, Aug 4, 2016
Filed:
Feb 19, 2016
Appl. No.:
15/047851
Inventors:
- Athens OH, US
Norikazu Harii - Yaminashi, JP
Uruguaysito Benavides-Peralta - Montevideo, UY
Mariana Gonzalez-Murguiondo - Montevideo, UY
Christopher J. Lewis - Athens OH, US
Douglas J. Goetz - Athens OH, US
Giorgio Napolitano - Athens OH, US
Cesidio Giuliani - Athens OH, US
Ramiro Malgor - Athens OH, US
Frank Schwartz - Vienna WV, US
Kelly D. McCall - Athens OH, US
International Classification:
A61K 31/4164
A61K 31/56
A61K 45/06
Abstract:
Treatment of autoimmune and/or inflammatory diseases associated with overexpression of Toll-like receptor 3 (TLR3) as well as Toll-like receptor 4 (TLR4) and/or TLR3/TLR4 signaling in nonimmune cells, monocytes, macrophages, and/or dendritic cells in association with related pathologies. The use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune and inflammatory diseases associated with TLR3 as well as TLR4 and/or TLR3/TLR4 cellular signaling in association with related pathologies is disclosed. Methods of treating a subject having a disease or condition associated with abnormal TLR-3 as well as TLR-4 and/or TLR3/TLR4 cellular signaling in association with related pathologies are also disclosed. The present disclosure also relates to the treatment of autoimmune-inflammatory pathologies and chemokine and cytokine-mediated diseases associated with TLR overexpression and signaling. The disclosure also relates to pharmaceutical formulations capable of inhibiting the IRF-3/Type 1 IFN/STAT/ISRE/IRF-1 pathway associated with Toll-like receptor overexpression or signaling.

Dynamic Biochemical Tissue Analysis Assays And Compositions

View page
US Patent:
20140186824, Jul 3, 2014
Filed:
Jun 29, 2012
Appl. No.:
14/130083
Inventors:
Monica Maki Burdick - Athens OH, US
Doug Goetz - Athens OH, US
Ventesh Sridmar Shirure - Athens OH, US
Ramiro Malgor - Athens OH, US
Vicente Resto - Galveston TX, US
Assignee:
Ohio University - Athens OH
International Classification:
G01N 33/569
US Classification:
435 61, 435 29, 435 721, 5303873
Abstract:
Described herein is a method, and compositions useful with the method, of analyzing a tissue from a subject. The method includes contacting a probe conjugate () including a probe molecule (), to a biological tissue from a subject. The probe conjugate () is contacted with the biological tissue () under a well defined and easily controlled force field(s) and that tends to result in an interaction between the molecular probe () and the tissue () and/or tends to disrupt such interactions. The resulting interaction of the molecular probe () with the tissue () is then quantified. The analytical methods may be useful for diagnostic and prognostic applications as well as in the discovery of novel drug delivery systems and novel therapeutic substances and targets.
Control profile
Ramiro M Malgor from Athens, OH, age ~59 Get Report